Collecting blood samples to study sickle cell disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect blood samples from both healthy individuals and those with unique red blood cell features related to sickle cell disease. The goal is to investigate potential new drug treatments for sickle cell disease by analyzing these samples. Participants will undergo a one- to two-hour outpatient procedure at the National Institutes of Health Clinical Center, where they will donate small volumes of blood for high throughput screening tests. The study focuses on identifying compounds that can inhibit the sickling of red blood cells, which is a critical issue in sickle cell disease.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Patients with sickle cell trait
* Patients with known hemoglobinopathies involving one or two genes for sickle hemoglobin
* Healthy volunteers for control experiments
* Age range: adults greater than or equal to 18 years of age

EXCLUSION CRITERIA:

* Subjects who are unable to comprehend the investigational nature of the laboratory research are ineligible to enroll in this protocol.
* As a safety precaution in handling the blood samples, patients with HIV, Hepatitis B or Hepatitis C will be excluded from the study. HIV, Hepatitis B or Hepatitits C testing will not be done under this study. Participants must be co-enrolled under another NIH protocol where the screening evaluation has been performed.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: William A Eaton, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Study coordinator: William A Eaton, M.D.
• Email: eaton@mail.nih.gov
• Phone: (301) 496-6030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Checking measles vaccine response in children with sickle cell disease

  This study tests whether infants and young children with sickle cell disease develop enough protection in the weeks after their measles vaccine.

  Recruiting at 3 sites Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio and 2 other locations · NCT07356050

• Senicapoc for Sickle Cell Disease with Hemolytic Phenotype

  A mid-stage study tests whether daily senicapoc helps people with sickle cell disease who have ongoing red blood cell breakdown and low hemoglobin, despite hydroxyurea, by comparing it to a placebo over 24 weeks.

  Recruiting at 4 sites Phase 2 Biossil Inc. · Toronto, Ontario and 3 other locations · NCT07282210

• Bone health, muscle strength, and frailty in postmenopausal women of African descent with sickle cell trait

  We will see if postmenopausal women of African descent who have sickle cell trait are more likely to have thinner bones, weaker muscles, or greater frailty than women without the trait.

  Recruiting UConn Health · Farmington, Connecticut · NCT07083531

• Using alendronate to treat osteonecrosis in adults with sickle cell disease

  This study is testing if a weekly medication called alendronate can help adults with sickle cell disease who have bone pain from osteonecrosis feel better and improve their bone health.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06016634

• Evaluating a single dose of CTX001 for treating transfusion-dependent beta-thalassemia and severe sickle cell disease

  This study is testing a single dose of a new treatment called CTX001 to see if it can help people with transfusion-dependent beta-thalassemia or severe sickle cell disease feel better.

  Recruiting at 6 sites Phase 3 Vertex Pharmaceuticals Incorporated · New York, New York and 5 other locations · NCT05477563

• Haploidentical stem cell transplantation for sickle cell disease

  This study is testing a new type of stem cell transplant for people with sickle cell disease to see if it can cure the disease while causing fewer complications.

  Recruiting at 4 sites Phase 2 University of Regensburg · Vienna and 8 other locations · NCT04201210

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.